The MMSE and MoCA for Screening Cognitive Impairment in Less Educated Patients with Parkinson’s Disease

Kim, Ji In; Sunwoo, Mun Kyung; Sohn, Young H.; Lee, Phil Hyu; Hong, Jin Yong

doi:10.14802/jmd.16020

Cited by 51 publications

(45 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have shown that the MOCA has high sensitivity when compared to the several cognitive screening tests available for MCI diagnosis in a number of populations, not only in PD. 9 , 11 , 19 - 21 A systematic review assessing the diagnostic performance of all cognitive tests for detecting of dementia due to several etiologies, including PD, concluded that the MOCA performed better than the other tests in detecting MCI. 20 Another study comparing the usefulness and diagnostic accuracy of the MOCA and the MMSE in diagnosing Alzheimer’s disease and MCI, concluded that the MOCA proved more sensitive and accurate for diagnosing MCI.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cut-off points of the Portuguese version of the Montreal Cognitive Assessment for cognitive evaluation in Parkinson’s disease

Almeida

Carvalho²,

Monteiro

et al. 2019

Dement. neuropsychol.

View full text Add to dashboard Cite

ABSTRACT. The Movement Disorder Society has published some recommendations for dementia diagnosis in Parkinson disease (PD), proposing the Montreal Cognitive Assessment (MOCA) as a cognitive screening tool in these patients. However, few studies have been conducted assessing the Portuguese version of this test in Brazil (MOCA-BR). Objective: the aim of the present study was to define the cut-off points of the MOCA-BR scale for diagnosing Mild Cognitive Impairment (PD-MCI) and Dementia (PD-D) in patients with PD. Methods: this was a cross-sectional, analytic field study based on a quantitative approach. Patients were selected after a consecutive assessment by a neurologist, after an extensive cognitive evaluation, and were classified as having normal cognition (PD-N), PD-MCI or PD-D. The MOCA-BR was then applied and 89 patients selected. Results: on the cognitive assessment, 30.3% were PD-N, 41.6% PD-MCI and 28.1% PD-D. The cut-off score on the MOCA-Br to distinguish PD-N from PD-D was 22.50 (95% CI 0.748-0.943) for sensitivity of 85.5% and specificity of 71.1%. The cut-off for distinguishing PD-D from MCI was 17.50 (95% CI 0.758-0.951) for sensitivity of 81.6% and specificity of 76%.

show abstract

Section: Discussionmentioning

confidence: 99%

“…However, there are other studies which assessed the MOCA in patients with Parkinson’s disease that had a lower educational level. 19 Also, these patients were not assessed for clinical staging. However, the subjects in this study had the disease for more than 60 months, and this enabled accurate diagnosis of parkinsonism etiology.…”

Section: Discussionmentioning

confidence: 99%

Cut-off points of the Portuguese version of the Montreal Cognitive Assessment for cognitive evaluation in Parkinson’s disease

Almeida

Carvalho²,

Monteiro

et al. 2019

Dement. neuropsychol.

View full text Add to dashboard Cite

show abstract

“…This is essential for their use because the MMSE and MoCA can be affected by differences in culture and language [ 8 ]. Furthermore, most of the published data for the MMSE or MoCA in patients with PD were obtained from highly educated subjects; however, many Korean PD patients have a low level of education [ 9 ]. Thus, the current study aimed to validate the two MMSE-MoCA conversion tables in Korean patients with PD.…”

mentioning

confidence: 99%

Validation of the Conversion between the Mini-Mental State Examination and Montreal Cognitive assessment in Korean Patients with Parkinson’s Disease

Kim

et al. 2018

JMD

View full text Add to dashboard Cite

Objective Two conversion tables between the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) have recently been established for Parkinson’s disease (PD). This study aimed to validate them in Korean patients with PD and to evaluate whether they could be influenced by educational level.Methods A total of 391 patients with PD who undertook both the Korean MMSE and the Korean MoCA during the same session were retrospectively assessed. The mean, median, and root mean squared error (RMSE) of the difference between the true and converted MMSE scores and the intraclass correlation coefficient (ICC) were calculated according to educational level (6 or fewer years, 7–12 years, or 13 or more years).Results Both conversions had a median value of 0, with a small mean and RMSE of differences, and a high correlation between the true and converted MMSE scores. In the classification according to educational level, all groups had roughly similar values of the median, mean, RMSE, and ICC both within and between the conversions.Conclusion Our findings suggest that both MMSE-MoCA conversion tables are useful instruments for transforming MoCA scores into converted MMSE scores in Korean patients with PD, regardless of educational level. These will greatly enhance the utility of the existing cognitive data from the Korean PD population in clinical and research settings.

show abstract

“…PD patients were diagnosed based on the United Kingdom Parkinson’s Disease Society Brain Bank diagnostic criteria and were recruited from March 2016 to February 2018. The inclusion criteria were as follows: 1) age between 20–79 years old, 2) Hoehn and Yahr (H&Y) stage 1–4, 3) presence of wearing-off phenomenon, 4) absence of significant cognitive impairment as determined by a Montreal Cognitive Assessment (MoCA) score ≥ 15 [ 7 ], 5) absence of significant depression as determined by a Geriatric Depression Scale (GDS) score ≤ 24 [ 8 ], and 6) consent to participate in the study. Patients with atypical parkinsonism, including multiple system atrophy, corticobasal syndrome, and progressive supranuclear palsy, were excluded from the study, as were patients who previously experienced side effects due to LCE.…”

Section: Methodsmentioning

confidence: 99%

Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease

Park¹,

Jo²,

Lee³

et al. 2020

JMD

View full text Add to dashboard Cite

Objective To investigate the efficacy of levodopa/carbidopa/entacapone (LCE) at bedtime for treating sleep disturbance in patients with Parkinson’s disease (PD) with motor fluctuations. Methods Participants included 128 PD patients with motor fluctuations. All patients were assessed for motor, nonmotor, and sleep-specific symptoms using the United Parkinson’s Disease Rating Scale (UPDRS), the Korean version of the Nonmotor Symptom Scale, the Parkinson’s Disease Sleep Scale (PDSS), the Epworth Sleepiness Scale, and the Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire (RBDSQ). We compared the baseline characteristics of patients with sleep disturbance (PDSS score < 120) and those without sleep disturbance (PDSS score ≥ 120). Thirty-nine patients with sleep disturbance who agreed to take LCE at bedtime completed 3-month follow-ups. We analyzed changes in the scores of motor, nonmotor, and sleep symptom scales over the 3 months. Results PD patients with sleep disturbance were at more advanced disease stages and had more severe motor, nonmotor, and sleep symptoms than those without sleep disturbance. Patients who took LCE at night showed improvements in motor (UPDRS part III, p = 0.007) and sleep symptoms (total PDSS, p < 0.001). Sleep features that benefitted from LCE included not only nocturnal motor components but also insomnia (PDSS items 2 and 3, p = 0.005 and p < 0.001) and rapid eye movement behavior disorder (PDSS item 6, p = 0.002; and RBDSQ, p < 0.001). Conclusion The use of LCE at bedtime may be a useful treatment for sleep disturbance in advanced PD patients with motor fluctuations.

show abstract

The MMSE and MoCA for Screening Cognitive Impairment in Less Educated Patients with Parkinson’s Disease

Cited by 51 publications

References 17 publications

Cut-off points of the Portuguese version of the Montreal Cognitive Assessment for cognitive evaluation in Parkinson’s disease

Cut-off points of the Portuguese version of the Montreal Cognitive Assessment for cognitive evaluation in Parkinson’s disease

Validation of the Conversion between the Mini-Mental State Examination and Montreal Cognitive assessment in Korean Patients with Parkinson’s Disease

Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease

Contact Info

Product

Resources

About